EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in non-small-cell lung cancer

Ann Oncol. 2019 Aug 1;30(8):1190-1192. doi: 10.1093/annonc/mdz185.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Carcinoma, Non-Small-Cell Lung*
  • ErbB Receptors / genetics
  • Humans
  • Lung Neoplasms*
  • Mutation

Substances

  • EGFR protein, human
  • ErbB Receptors